GlassScriptPhysician profile
Erika Dawn Glas
NPI 1336348499
$3,536.56
in general payments reported to CMS, 2019-2025
46 companies · $591 in 2025
The $591 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $352 · 2021: $830 · 2022: $507 · 2023: $379 · 2024: $371 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.05 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.37 | 2019-2025 | |
| Therapeuticsmd, INC. | $282.97 | 2019-2022 | |
| Astellas Pharma US INC | $273.18 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $236.04 | 2019-2025 | |
| Daiichi Sankyo INC. | $232.58 | 2019-2023 | Injectafer |
| Hologic Sales and Service, LLC | $197.51 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $194.32 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $143.97 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $135.34 | 2020-2022 | |
| Exeltis, USA INC. | $130.68 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.12 | 2019-2022 | |
| Sage Therapeutics, LLC | $110.29 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $80.73 | 2022-2024 | Phexxi |
| Myovant Sciences INC. | $77.53 | 2021-2022 | |
| Vivus LLC | $71.86 | 2021-2024 | Qsymia |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optumhealth Care Solutions, LLC | $65.30 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Roche Diagnostics Corporation | $64.55 | 2019-2021 | |
| Pfizer INC. | $60.92 | 2022-2025 | |
| Coopersurgical, INC. | $58.69 | 2021-2025 | Paragard T 380a |
| Agile Therapeutics, INC. | $54.59 | 2021-2023 | Twirla |
| Shield Therapeutics INC | $53.11 | 2022-2023 | Accrufer |
| Avion Pharmaceuticals | $48.42 | 2021-2023 | Balcoltra |
| Lupin INC. | $44.72 | 2019-2020 | |
| Amgen INC. | $41.96 | 2019 | |
| Myriad Women'S Health, INC. | $37.50 | 2023 | Myrisk |
| Organon LLC | $37.06 | 2022-2023 | Nexplanon |
| Davol INC. | $32.23 | 2021-2023 | Arista Ah Flexitip |
| Millicent US INC | $29.90 | 2025 | Femlyv, Intrarosa |
| Innovation Technologies INC | $29.75 | 2025 | Irrisept |
| Coloplast Corp | $27.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $25.84 | 2019-2020 | |
| Heron Therapeutics, INC. | $21.34 | 2023 | Zynrelef |
| Eisai INC. | $20.56 | 2020 | |
| Dexcom, INC. | $19.81 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $18.46 | 2023 | Hemosphere |
| Stryker Corporation | $18.02 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.83 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.74 | 2023 | Dsuvia |
| Becton, Dickinson and Company | $17.25 | 2021 | |
| Smith+Nephew, INC. | $16.50 | 2019 | |
| Olympus America INC. | $16.46 | 2024 | Olympus |
| Baxter Healthcare | $15.84 | 2025 | Perclot |
| Boston Scientific Corporation | $14.60 | 2023 | Advantage System |
| Scynexis, INC. | $14.18 | 2022 | |
| Currax Pharmaceuticals LLC | $14.00 | 2022 | |
| Minerva Surgical, INC | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Glas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.